GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration

The application includes data for a new, 50 mg tablet that can be dispersed in water and which was developed to facilitate use in children.